266 completed, 20 active not recruiting, 19 terminated, 15 recruiting. 348 Phase 3, 16 Phase 2.
Follow Psoriasis: new trials by email Literature Review of Psoriasis trials Research Report on Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis | Phase 3 | Not yet recruiting | Takeda | 644 | 2027-01-11 | 2026-10-27 |
| Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO/PsA Study Completers Deucravacitinib - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | Not yet recruiting | Bristol-Myers Squibb | 2300 | 2026-12-31 | 2026-09-03 |
| A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis Zasocitinib - Palmoplantar Psoriasis | Phase 3 | Not yet recruiting | Takeda | 40 | 2026-11-16 | 2026-11-04 |
| Efficacy of Crisaborole 2% Ointment Versus Tacrolimus 0.1% Ointment in the Treatment of Intertriginous and/or Anogenital Psoriasis. Crisaborole 2% topical ointment, tacrolimus ointment 0.1% - Psoriasis, Psoriasis Genital | Phase 3 | Not yet recruiting | Cairo University | 40 | 2026-10-25 | 2026-10-27 |
| A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis TQH3906 capsules, Deucravacitinib tablets 6 mg, TQH3906 Capsules placebo - Psoriasis | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | 400 | 2026-09-02 | 2026-09-09 |
| Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis Tofacitinib, Imatinib, tofacitinib Placebo - Palmoplantar Pustulosis (PPP) | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 135 | 2026-08-01 | 2026-08-03 |
| Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis Zasocitinib - Psoriatic Arthritis | Phase 3 | Recruiting | Takeda | 1182 | 2026-03-11 | 2026-09-09 |
| Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis Ponesimod - Moderate-to-severe Chronic Plaque Psoriasis | Phase 3 | Recruiting | Vanda Pharmaceuticals | 300 | 2026-02-17 | 2026-09-22 |
| Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis Cosmetic patch containing urea applicated daily for 3 months, Placebo patch application - Nail Psoriasis, Nail Damage | Phase 3 | Recruiting | Wooshin Labottach Co., Ltd. | 72 | 2026-02-01 | 2026-01-26 |
| Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III) Total coumarin (TC) cream, Vehicle cream - Psoriasis Vulgaris, Topical Administration | Phase 3 | Recruiting | Psoriasis Research Institute of Guangzhou | 300 | 2026-02-01 | 2026-02-23 |
| A Study of Picankibart in Patients With Active Psoriatic Arthritis Placebo, Picankibart - Psoriatic Arthritis | Phase 2 / Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 222 | 2025-12-18 | 2026-03-20 |
| A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis IBI112, placebo - Psoriasis | Phase 3 | Recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 104 | 2025-12-03 | 2025-12-22 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis Deucravacitinib, Placebo - Plaque Psoriasis | Phase 3 | Recruiting | Bristol-Myers Squibb | 366 | 2025-12-03 | 2026-10-27 |
| A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis Bimekizumab, Placebo - Palmoplantar Pustulosis | Phase 3 | Recruiting | UCB Biopharma SRL | 320 | 2025-11-14 | 2026-08-27 |
| A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis Sonelokimab - Arthritis, Psoriatic | Phase 3 | Enrolling by invitation | MoonLake Immunotherapeutics AG | 1560 | 2025-11-13 | 2026-09-09 |
| A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis ) LZM012 - Psoriasis | Phase 3 | Completed | Livzon Pharmaceutical Group Inc. | 244 | 2025-06-23 | 2026-08-05 |
| Comparison of Otezla to SFA-002 to Placebo in Plaque Psoriasis Patients SFA002, Otezla, Placebo - Psoriasis (PsO) | Phase 2 / Phase 3 | Not yet recruiting | SFA Therapeutics | 125 | 2025-06-01 | 2025-03-11 |
| A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy piclidenoson, Placebo - Plaque Psoriasis | Phase 3 | Not yet recruiting | Can-Fite BioPharma | 705 | 2025-06-01 | 2025-04-29 |
| Efficacy and Safety of Ixekizumab in Patients with Refractory Guttate Psoriasis Ixekizumab - Guttate Psoriasis | Phase 2 / Phase 3 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2025-05-01 | 2025-02-10 |
| Sulodexide in Controlling the Recurrence of Psoriasis Sulodexide, Placebo - Psoriasis (PsO), Randomised Controlled Trial | Phase 3 | Enrolling by invitation | Xijing Hospital | 160 | 2025-04-20 | 2025-05-21 |
Showing 20 of 348. Sign in to see all of them.
Arthritis, Psoriatic (105) · Skin Diseases (17) · Pruritus (14) · Arthritis (13) · Lymphoma, Follicular (11) · Plaque, Amyloid (9) · Bronchiolitis Obliterans Syndrome (7) · Dermatitis (6) · Inflammation (5) · Arthritis, Juvenile (3) · Arthritis, Rheumatoid (3) · Chronic Disease (3) · Joint Diseases (3) · Obesity (3)
Skin and Connective Tissue Diseases (348) · Skin Diseases, Papulosquamous (346) · Skin Diseases (331) · Bone Diseases (105) · Spinal Diseases (105) · Musculoskeletal Diseases (104) · Spondylitis (104) · Joint Diseases (103) · Spondylarthritis (102) · Spondylarthropathies (102) · Arthritis (93) · Pathological Conditions, Signs and Symptoms (34) · Immune System Diseases (20) · Signs and Symptoms (17)
secukinumab (43) · Adalimumab (36) · Ustekinumab (29) · Etanercept (24) · risankizumab (21) · apremilast (20) · guselkumab (19) · Methotrexate (17) · bimekizumab (15) · tofacitinib (14) · Infliximab (13) · ixekizumab (13) · deucravacitinib (12) · brodalumab (11) · golimumab (7)
Novartis Pharmaceuticals (37) · Amgen (26) · AbbVie (23) · Janssen Research & Development, LLC (19) · UCB Biopharma SRL (15) · Eli Lilly and Company (14) · Pfizer (13) · Abbott (11) · Bristol-Myers Squibb (11) · Centocor, Inc. (7) · Merck Sharp & Dohme LLC (7) · Takeda (6) · Bausch Health Americas, Inc. (5) · Janssen Pharmaceutical K.K. (5) · AbbVie (prior sponsor, Abbott) (4)
United States (176) · Germany (131) · Canada (128) · Poland (122) · Spain (96) · Hungary (87) · United Kingdom (84) · Czechia (78) · France (77) · Australia (70) · Russia (70) · Italy (63) · Japan (61) · Belgium (59) · China (46)
Beverly Paperiello (3) · Victoria Butners (3)
PMID 32816215, PMID 37906417, PMID 37316690, PMID 38446397, PMID 30739254, PMID 31667790, PMID 35305260, PMID 38488975, PMID 39120849, PMID 39578348, PMID 41060492, PMID 41800601, PMID 27573260, PMID 27576559, PMID 31054118, PMID 34110605, PMID 34795065, PMID 34921669, PMID 35544084, PMID 36751950, PMID 37341961, PMID 37400681, PMID 37950894, PMID 39073712, PMID 39120848, PMID 40241921, PMID 40286813, PMID 40886218, PMID 41359217, PMID 41580158, PMID 26953848, PMID 27299809, PMID 30018799, PMID 31077258, PMID 31112005, PMID 31203228, PMID 31909868, PMID 31964419, PMID 32006348, PMID 32207067, PMID 32531798, PMID 33748660, PMID 34536218, PMID 34870800, PMID 35279805, PMID 35393269, PMID 36526796, PMID 36642439, PMID 36931693, PMID 36958766
2016 (18), 2023 (14), 2014 (12), 2015 (9), 2017 (9), 2018 (9), 2019 (6), 2009 (5), 2005 (4), 2025 (1)